These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21970687)

  • 1. Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration.
    Cole S; Bagal S; El-Kattan A; Fenner K; Hay T; Kempshall S; Lunn G; Varma M; Stupple P; Speed W
    Xenobiotica; 2012 Jan; 42(1):11-27. PubMed ID: 21970687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to optimize brain penetration in drug discovery.
    Liu X; Chen C
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):505-12. PubMed ID: 16022187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restricting CNS penetration of drugs to minimise adverse events: role of drug transporters.
    Bagal S; Bungay P
    Drug Discov Today Technol; 2014 Jun; 12():e79-85. PubMed ID: 25027378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case study: adapting in vitro blood-brain barrier models for use in early-stage drug discovery.
    Vandenhaute E; Sevin E; Hallier-Vanuxeem D; Dehouck MP; Cecchelli R
    Drug Discov Today; 2012 Apr; 17(7-8):285-90. PubMed ID: 22033197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysing molecular polar surface descriptors to predict blood-brain barrier permeation.
    Shityakov S; Neuhaus W; Dandekar T; Förster C
    Int J Comput Biol Drug Des; 2013; 6(1-2):146-56. PubMed ID: 23428480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions.
    Zolk O; Fromm MF
    Clin Pharmacol Ther; 2011 Jun; 89(6):798-805. PubMed ID: 21471963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
    Mahar Doan KM; Humphreys JE; Webster LO; Wring SA; Shampine LJ; Serabjit-Singh CJ; Adkison KK; Polli JW
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1029-37. PubMed ID: 12438524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the brain--surmounting or bypassing the blood-brain barrier.
    Potschka H
    Handb Exp Pharmacol; 2010; (197):411-31. PubMed ID: 20217538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central nervous system penetration for small molecule therapeutic agents does not increase in multiple sclerosis- and Alzheimer's disease-related animal models despite reported blood-brain barrier disruption.
    Cheng Z; Zhang J; Liu H; Li Y; Zhao Y; Yang E
    Drug Metab Dispos; 2010 Aug; 38(8):1355-61. PubMed ID: 20427691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 13. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position.
    Kalvass JC; Polli JW; Bourdet DL; Feng B; Huang SM; Liu X; Smith QR; Zhang LK; Zamek-Gliszczynski MJ;
    Clin Pharmacol Ther; 2013 Jul; 94(1):80-94. PubMed ID: 23588303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in brain penetration evaluation in drug discovery and development.
    Liu X; Chen C; Smith BJ
    J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ionization-specific QSAR models of blood-brain penetration of drugs.
    Lanevskij K; Japertas P; Didziapetris R; Petrauskas A
    Chem Biodivers; 2009 Nov; 6(11):2050-4. PubMed ID: 19937840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid screening of blood-brain barrier penetration of drugs using the immobilized artificial membrane phosphatidylcholine column chromatography.
    Yoon CH; Kim SJ; Shin BS; Lee KC; Yoo SD
    J Biomol Screen; 2006 Feb; 11(1):13-20. PubMed ID: 16314407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of Pgp function by boswellic acids.
    Weber CC; Reising K; Müller WE; Schubert-Zsilavecz M; Abdel-Tawab M
    Planta Med; 2006 May; 72(6):507-13. PubMed ID: 16773534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood-brain barrier permeability considerations for CNS-targeted compound library design.
    Hitchcock SA
    Curr Opin Chem Biol; 2008 Jun; 12(3):318-23. PubMed ID: 18435937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The concept of fraction of drug transported (ft ) with special emphasis on BBB efflux of CNS and antiretroviral drugs.
    Prasad B; Unadkat JD
    Clin Pharmacol Ther; 2015 Apr; 97(4):320-3. PubMed ID: 25669655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving compound quality through in vitro and in silico physicochemical profiling.
    van de Waterbeemd H
    Chem Biodivers; 2009 Nov; 6(11):1760-6. PubMed ID: 19937820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.